



Contacts: Bret L. Udem  
Media Relations  
Tel. (425) 493-2293  
Fax. (425) 493-2010

FOR RELEASE  
July 9, 2004

## COMBIMATRIX AND STRAND GENOMICS ENTER INTO CO-MARKETING AGREEMENT

Newport Beach, Calif. – (BUSINESS WIRE) – July 9, 2004 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group has entered into a co-marketing agreement with Strand Genomics to market its product avadis, a data analysis software tool for microarray gene expression.

"Strand Genomics is rapidly becoming a recognized provider of quality commercial software serving the microarray analysis marketplace," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We look forward to offering our growing customer base products designed to make it easier to order, manage, analyze and interpret their CustomArray™ microarray data."

"We are excited to partner with CombiMatrix and believe their new revolutionary CustomArray™ products will bring tremendous advantages to researchers in the molecular lifescience marketplace," said Vijay Chandru, Ph.D., CEO of Strand Genomics.

avadis is a data analysis and visualization tool that combines scalable analytical algorithms with powerful and interactive visualization to derive valuable insights from gene expression data. avadis enables CombiMatrix's customers to seamlessly order, redesign, and reorder CustomArrays through various data analysis approaches within the avadis software. It also provides a wide range of clustering techniques and statistical tests that make up the complete analysis toolset. avadis is a comprehensive solution that meets all the needs of gene expression researchers with a superior performance-to-price feature.

### **ABOUT CUSTOMARRAY™**

CustomArrays™ are semiconductor-based microarrays in a standard 1" x 3" slide format. CustomArray enables total customization of content with complete flexibility allowing the researcher to study any genome, any gene or any species in any quantity desired. CombiMatrix synthesizes oligonucleotides *in situ* to build unique CustomArrays. This revolutionary technology allows CombiMatrix to deliver CustomArrays in days. Sensitivity and performance metrics are available on the company's main web site and at [www.customarray.com](http://www.customarray.com).

Researchers can place orders for CustomArray products by contacting CombiMatrix at (800) 985-2269 or by accessing CombiMatrix's order site at [www.customarray.com](http://www.customarray.com).

### **ABOUT STRAND GENOMICS PVT LTD**

**Strand** is a global life sciences informatics company focused on software for drug discovery and development. Strand has leveraged its core strengths in data mining and predictive modeling to develop its products avadis and truPK. avadis is a comprehensive microarray data analysis and visualization software. truPK is an in-silico ADME (PharmacoKinetic) predictive modeling technology developed by Strand. Strand offers the truPK models for licensing and consulting services for custom model building. Strand is based in Bangalore, India, with a marketing and corporate development office in California. For more information on Strand, visit the company's website at <http://www.strandgenomics.com>, for more information on avadis visit <http://avadis.strandgenomics.com> and for more information on truPK visit <http://trupk.strandgenomics.com>.

## **ABOUT ACACIA RESEARCH CORPORATION**

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray™ brand. CombiMatrix's Express Track<sup>sm</sup> drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia's DMT technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at [www.acaciaresearch.com](http://www.acaciaresearch.com).

### **Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:**

*This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.*